PITTSBURGH & HAMBURG, Germany--(BUSINESS WIRE)--Jan. 30, 2006--Cellomics, Inc., a business unit within the Fisher Biosciences group, and Evotec Technologies GmbH announced today that they have entered into a worldwide, non-exclusive patent license agreement. The agreement will provide Evotec Technologies with Cellomics’ core High Content Screening (HCS) patent portfolio, which includes both broad claims to HCS technology and specific classes of HCS assays such as cytoplasm-nuclear translocation, characterization of cellular toxicity, and receptor internalization. This is a significant extension of the portfolio of cellular biology applications for Evotec Technologies in the area of automated high-throughput HCS systems.
